Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai

      Allergan Aesthetics Logo (PRNewsfoto/AbbVie)

      News provided by

      AbbVie

      Sep 25, 2025, 05:00 ET

      Share this article

      Share this article


      • New AA (Allergan Aesthetics) Signature™ multimodal treatment approach to be presented at AMWC Dubai following successful launch in 25 countries so far this year.
      • Experts to explore the paradigm shift in medical aesthetics and decode new AA Signature™ approach at Allergan Medical Institute (AMI) symposium.
      • Skin Quality Multimodal Mastery explored in depth at Global Medical Affairs symposium as part of Allergan Aesthetics' continued commitment to advancing skin quality.

      IRVINE, Calif., Sept. 25, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is set to present comprehensive AA Signature™ multimodal treatment approach to global audience, at the upcoming Internationally recognized Aesthetic Anti-Aging Medicine World Congress (AMWC), taking place in Dubai from Wednesday 1 – Friday 3 October 2025.

      The AA Signature™ treatment approach harnesses Allergan Aesthetics' leading product portfolio and is supported by advanced education and business resources for healthcare professionals. Designed to meet evolving patient needs and enhance clinical practice, AA Signature™ has been successfully launched in over 25 countries* this year and is planned for further expansion. The protocol-driven methodology currently addresses different globally recognized patient needs including Lift Up, Distinct Definition, and improved skin quality.

      "Aesthetic trends worldwide are shifting toward a more natural, individualized look. The AA Signature™ treatment approach is designed to meet these emerging patient needs, offering a holistic method that recognizes and aligns with each patient's unique goals. The approach leverages Allergan Aesthetics' advanced and versatile portfolio to empower healthcare professionals to deliver multimodal treatment plans for tailored results, strengthening patient relationships and encouraging long-term retention," said Mark Wilson, SVP, International Allergan Aesthetics. We've received excellent feedback from healthcare practitioners since launching AA Signature™, and we look forward to continuing to showcase real-world results and data in the coming months."

      AMWC Dubai 2025 AMI Symposium
      The Allergan Medical Institute hosted symposium 'Design your patients' look with the NEW Signature approach by Allergan Aesthetics and a decade of MD Codes™ excellence' will take place at 11AM-1PM on Wednesday, 1 October in Baniyas Ballroom 1, Grand Hyatt Dubai.

      World-renowned experts including plastic surgeon and creator of the MD Codes™ system Dr Mauricio de Maio will explore the paradigm shift in medical aesthetics and decode the new AA Signature™ approach.

      A live injection of AA Signature™ Lift Up will be performed, focusing on how the multimodal approach can help address patient needs including added lift, structure and skin firmness as research finds patients long for a lifted and more defined appearance1,2†.

      Allergan Aesthetics Global Medical Affairs Symposium on Skin Quality Multimodal Mastery
      A single-strategy treatment plan may not be enough to unlock the skin's full potential7, and a multimodal approach is the focus of this year's medical symposium, 'Mastering Skin Quality - Integrating Aesthetic Modalities for Holistic Skin Quality Improvement' on Wednesday, 1 October at 2PM-4PM in Al Ameera Ballroom 2, Grand Hyatt Dubai.

      With 94% of people wanting to improve their facial skin quality3‡, Allergan Aesthetics brings together globally renowned leaders in aesthetics Dr. Rami Abadi, Dr. Sylwia Godlewska, Dr. Maurizio Cavallini and Dr. Mansi Mukherjee to offer a deep dive into understanding patient needs related to skin quality and exploring the integration of a holistic, multi-modal aesthetic approach—including hyaluronic acid (HA), biostimulators, and hybrid injectables—within clinical practice to enhance skin quality and elevate patient satisfaction.

      Meet The Experts
      Allergan Aesthetics will host a series of Meet the Experts sessions live from booth B100 across the three day event, featuring:

      • Predictable, proven, preferred with Dr Mansi Mukherjee and Prof Yehia El Garem
      • From patients' needs to practice: Enhancing long term value with AA Signature™ with Dr Akiko Imaizumi and Dr Rami Abadi
      • SKIN360 by AA Signature™ with Dr Raafat Lakis and Dr Minoka Nadesan
      • LIFT UP by AA Signature™ with Dr Sami Alissa and Dr Wei-Ting Chang

      Allergan Aesthetics Booth – B100
      Attendees can discover more about the AA Signature approach and explore the Allergan Aesthetics facial aesthetics portfolio with immersive product experiences at networking opportunities at the booth.

      New clinical data 
      Additionally, a personalized aesthetics approach and skin quality are topics that feature amongst 7 e-posters that have been accepted across various products, treatments and indications, furthering Allergan Aesthetics' commitment. Titles and authors include:

      Presentation Topic

      Poster Title

      Authors

      MaxDiff Characteristics Likely to Treat - Middle Eastern Women ABS

      Facial and Body Aesthetic Concerns and Treatment Interests Among Middle Eastern Women: Results From Middle Eastern Female-Identifying Respondents of a Large US Survey of Aesthetically Inclined Adults

      Raafat Lakis, Mona Sadeghpour, Omer Ibrahim, Amir Moradi, Mohammad Saleh Al-Khowailed, Ammar Raza, Nazanin Ashourian, Elena Dimitrijevic, Sara Sangha

      Personalized Ax - Lift

      Personalized Aesthetic Treatment for Nonsurgical Lift Effect Using Multimodal Portfolio of Injectables

      Juliana Chieppe; Jake Sloane; Peter Peng; Emily Schultz; Wang Ye; Ahmed Yasin

      Personalized Ax - Skin

      Personalized Aesthetic Treatment to Improve Common Skin Quality Needs Using a Multimodal Portfolio of Injectables

      Jake Sloane; Juliana Chieppe; Yuexing Song; Peter Peng; Emily Schultz; Ahmed Yasin

      Juvéderm® VYCROSS™, BOTOX® upper and midface treatment and PROs

      Infraorbital and Periorbital Rejuvenation with Sequential Use of Hyaluronic Acid Fillers and OnabotulinumtoxinA

      Gregory Goodman; Frank Lin; Samira Baharlou; Sarah Boxley; Pierre Cuvelier; Cara McDonald; Joan Vandeputte; Ivar Van Heijningen; Julia K. Garcia; Traci Baker; Smita Chawla; Carola de la Guardia

      Juvéderm® VOLUMA temple China study

      Improvement in Temple Hollowing With VYC-20L Filler: A Multicenter, Randomized Controlled Trial of Safety and Effectiveness in a Chinese Population

      Yun Xie, Qingfeng Li, Jiaming Sun, Lei Wang, Qian Tan, Chengyuan Wang, Dong Li, Hongyi Zhao, Chenliang Deng, Jingli Shi, Smita Chawla

      Juvéderm® VOLUMA temple repeat treatment and PROs from US study

      Efficacy and Safety of VYC-20L Hyaluronic Acid Filler in Temple Hollowing: Initial Treatment and Maintenance Results from a Multicenter Study

      José R. Montes, Derek Jones, Brian Biesman, Kenneth Beer, Deirdre Hooper, Steve Yoelin, Leslie Baumann, Kelly Leung, Shirley Chung, Smita Chawla

      HArmonyCa™ Int'l Interim

      An International, Multicenter, Evaluator-blinded, Randomized, Parallel-Group, Controlled Study of the Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation

      A Nikolis, N Demosthenous, S Humphrey, F Urdiales, M Salomon, A Schumacher

      Notes to Editors

      About AbbVie

      AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com.

      About Allergan Aesthetics

      At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit. www.allerganaesthetics.com.

      Forward-Looking Statements 

      Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 

      Global Media:

      Investors:

      Michael Salzillo

      Liz Shea

      [email protected] 

      [email protected]  



      U.S. Media:


      Adelle Infante


      [email protected]  


      Disclaimers

      Material developed and funded by Allergan Aesthetics, an AbbVie company.

      Copyright 2023 AbbVie. All rights reserved. All trademarks are the property of their respective owners.

      Footnotes:

      *AA Signature has rolled out in the following 25 countries so far this year: Spain / Iberia, Turkey, Brazil, Australia, Taiwan, France, Mexico, Columbia, Argentina, Chile, Italy, Bulgaria, Sweden, Finland, Denmark, Norway, China, GULF, South Africa, and other Central and Eastern Europe countries.    

      †Qualitative data from an online community platform captured over 5 days with a range of consumer types (naïve considerers, engaged considerers, users) from a range of ages (20–34, 34–49 and 50+) from Canada, Brazil, China.

      ‡94% of 14,584 people interviewed in a global survey. People desired to improve their facial skin, and terms such as radiance and healthy, glowing skin were requested by patients seeking improvements in their appearance. The term 'skin quality' encompasses this collection of desired outcomes.  

      References:

      1. Chiu A et al. Clin Cosmet Investig Dermatol. 2023;16:1521–32.
      2. Allergan Aesthetics. Data on File. Consumer Filler. March 2021.
      3. Allergan Aesthetics. Data on file. REF-100241. Skin Health Media Statistics. August 2022.
      4. Allergan Aesthetics. Data on file. Consumer Beauty Insights Survey 2021. August 2021.
      5. Beauty Independent. Forget Beauty. These Days, Skincare Is All About Health. But What Exactly Is Skin Health? Available at: https://www.beautyindependent.com/skincare-what-exactly-skin-health/. [Accessed September 2024]. 
      6. Allergan Aesthetics. Data on File. The Lower Face Customer & HCP Journey: Qualitative Research Report. May 2024.
      7. Goldie K et al. Clin Cosmet Investig Dermatol 2021;14:643–54.
      8. Humphrey S, et al. Dermatol Surg. 2021;47(7):974–81. 

      SOURCE AbbVie

      Modal title

      Also from this source

      Allergan Aesthetics Celebrates Eight Years of Engaging Girls in STEM Through Continued Partnership with Girls Inc.

      Allergan Aesthetics, an AbbVie company, is celebrating eight years of partnership with Girls Inc., a nonprofit organization dedicated to inspiring...

      U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease

      AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI®...

      More Releases From This Source

      Explore

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      Cosmetics and Personal Care

      Cosmetics and Personal Care

      Pharmaceuticals

      Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.